PT  - JOURNAL ARTICLE
AU  - Emanuele Pontali
AU  - Mario C. Raviglione
AU  - Giovanni Battista Migliori
ED  - ,
TI  - Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
AID  - 10.1183/16000617.0035-2019
DP  - 2019 Jun 30
TA  - European Respiratory Review
PG  - 190035
VI  - 28
IP  - 152
4099  - http://err.ersjournals.com/content/28/152/190035.short
4100  - http://err.ersjournals.com/content/28/152/190035.full
SO  - EUROPEAN RESPIRATORY REVIEW2019 Jun 30; 28
AB  - Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes.After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9–10 months.The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.The article reviews the evolution of the strategies and regimens to manage drug-resistant tuberculosis, opening a window on future perspectives. http://bit.ly/2Q1Rhx0